Höfer Julia, Mag.

University / Clinic: Department of Urology
Institute: Urologielabor, FK Gebäude
 
Research Area: Protein inhibitor of activated STAT (PIAS)1 in prostate cancer

Email: julia.hoefer@i-med.ac.at
Web: www.zculig.org


Research Topic:
Protein inhibitor of activated STAT (PIAS)1 in prostate cancer

Selected publications:
 
  Höfer J, Akbor M, Handle F, Ofer P, Puhr M, Parson W, Culig Z, Klocker H, Heidegger I
Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide.
Oncotarget. 2016 Sep 13;7(37):59781-59794. doi: 10.18632/oncotarget.10926.

  Handle F, Erb H, Luef B, Höfer J, Dietrich D, Parson W, Kristiansen G, Santer F, Culig Z
SOCS3 Modulates the Response to Enzalutamide and Is Regulated by Androgen Receptor Signaling and CpG Methylation in Prostate Cancer Cells.
Mol Cancer Res. 2016 Jun;14(6):574-85. doi: 10.1158/1541-7786.MCR-15-0495. Epub 2016 Apr 6.

  Heidegger I, Höfer J, Luger M, Pichler R, Klocker H, Horninger W, Steiner E, Jochberger S, Culig Z
Is Eotaxin-1 a serum and urinary biomarker for prostate cancer detection and recurrence?
Prostate. 2015 Dec;75(16):1904-9. doi: 10.1002/pros.23086. Epub 2015 Aug 26.

  Höfer J, Kern J, Ofer P, Eder I, Schäfer G, Dietrich D, Kristiansen G, Geley S, Rainer J, Gunsilius E, Klocker H, Culig Z, Puhr M
SOCS2 correlates with malignancy and exerts growth-promoting effects in prostate cancer.
Endocr Relat Cancer. 2014 Jan 30;

  Puhr M, Höfer J, Neuwirt H, Eder I, Kern J, Schäfer G, Geley S, Heidegger I, Klocker H, Culig Z
PIAS1 is a crucial factor for prostate cancer cell survival and a valid target in docetaxel resistant cells.
Oncotarget. 2014 Dec 15;5(23):12043-56.

  Höfer J, Schäfer G, Klocker H, Erb H, Mills I, Hengst L, Puhr M, Culig Z
PIAS1 is increased in human prostate cancer and enhances proliferation through inhibition of p21.
Am J Pathol. 2012 May;180(5):2097-107. Epub 2012 Mar 23.

  Puhr M, Höfer J, Schäfer G, Erb H, Oh S, Klocker H, Heidegger I, Neuwirt H, Culig Z
Epithelial to Mesenchymal Transition Leads to Docetaxel Resistance in Prostate Cancer and is Mediated by Reduced Expression of miR-200c and miR-205.
Am J Pathol. 2012 Oct 3. pii: S0002-9440(12)00653-0. doi: 10.1016/j.ajpath.2012.08.011

  Shariat S, Chromecki T, Höfer J, Barbieri C, Scherr D, Karakiewicz P, Roehrborn C, Montorsi F, Culig Z, Cavarretta I
Soluble gp130 Regulates Prostate Cancer Invasion and Progression in an Interleukin-6 Dependent and Independent Manner.
J Urol. 2011 Nov;186(5):2107-14.

  Tancevski I, Demetz E, Eller P, Duwensee K, Höfer J, Heim C, Stanzl U, Wehinger A, Auer K, Karer R, Huber J, Schgoer W, Van Eck M, Vanhoutte J, Fievet C, Stellaard F, Rudling M, Patsch J, Ritsch A
The liver-selective thyromimetic T-0681 influences reverse cholesterol transport and atherosclerosis development in mice.
PLoS One. 2010 Jan 15;5(1):e8722.

  Tancevski I, Wehinger A, Demetz E, Höfer J, Eller P, Huber E, Stanzl U, Duwensee K, Auer K, Schgoer W, Kuhn V, Fievet C, Stellaard F, Rudling M, Foeger B, Patsch J, Ritsch A
The thyromimetic T-0681 protects from atherosclerosis.
J Lipid Res. 2009 May;50(5):938-44.